Morphic Holding, a preclinical biotech developing oral integrin inhibitors for chronic diseases, raised $90 million by offering 6 million shares at $15, within the range of $14 to $16. The company originally planned to sell 5 million shares. Morphic Holding plans to list on the Nasdaq under the symbol MORF. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as lead managers on the deal.
